Subsequently, on August 19th, 2024, the combination of lazertinib and amivantamab received approval from the US Food and Drug Administration as a first‐line treatment for locally advanced or metastatic NSCLC with EGFR exon 19 deletion or exon 21 L858R mutations [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.